Pharmaceuticals APAC

APAC Migraine Drugs Market Analysis, 2024–2034

Updated Reviewed by Chandani Patel

APAC Migraine Drugs Market Industry Trends and Forecast to 2034: Segmented by (Drug Class, Use, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

APAC · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $1.86 Bn Placeholder estimate
Estimate 2025 $2.03 Bn 23.2% of the global market
Projected 2034 $4.45 Bn 119% Adds $2.42 Bn over 9 forecast years
CAGR 2025–2034 9.1% Faster than 45% of 180 Pharmaceuticals markets here
Key players 6 +1
  • APAC is 23.25% of the global market.
  • Among regions, the largest is North America at $4.84 Bn.
  • Fastest growing: Africa at 9.5% a year.
  • APAC ranks 2nd of 6 by size among regions.

Market size projection

APAC

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$2.42 Bn total, 2026–2034

Year-by-year market size, 2024–2034
Migraine Drugs Market market size by year, APAC
YearMarket sizeChange that yearSince 2025
2024 (estimate) $1.86 Bn — —
2025 (base) $2.03 Bn +$169.6 Mn —
2026 (forecast) $2.22 Bn +$185.1 Mn +9.1%
2027 (forecast) $2.42 Bn +$201.9 Mn +19%
2028 (forecast) $2.64 Bn +$220.3 Mn +29.9%
2029 (forecast) $2.88 Bn +$240.3 Mn +41.7%
2030 (forecast) $3.14 Bn +$262.2 Mn +54.6%
2031 (forecast) $3.43 Bn +$286.0 Mn +68.6%
2032 (forecast) $3.74 Bn +$312.1 Mn +84%
2033 (forecast) $4.08 Bn +$340.5 Mn +100.7%
2034 (forecast) $4.45 Bn +$371.5 Mn +119%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

APAC Migraine Drugs Market Analysis at a glance
Market size, 2025$2.03 Bn placeholder estimate
Forecast, 2034$4.45 Bn placeholder estimate
Growth (CAGR), 2025–20349.1% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsDrug class, use and end user (see all)
Key playersPfizer Inc., AbbVie Inc., Teva Pharmaceutical, Eli Lilly and Company, Amgen Inc. and 1 more (see all)
Active clinical trials58 in Asia PacificSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Asia Pacific. Retrieved 12 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The APAC Migraine Drugs Market Analysis Executive Summary

Migraine drugs stop or prevent migraine attacks, including newer CGRP-blocking medicines and triptans.

Key segments of the migraine Drugs market include drug class (CGRP Antibodies, Gepants and Triptans) and use (Acute Treatment and Prevention).

Bar chart: Asia Pacific Migraine Drugs market size, 2024–2034, placeholder estimates. $1.86 Bn in 2024, $2.03 Bn in 2025 and $4.45 Bn in 2034, 9.1% CAGR.
Asia Pacific Migraine Drugs market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

APAC Migraine Drugs Market Dynamics

Market Growth Drivers

An ageing population, more people living with brain and nerve diseases, better diagnosis and the first disease-modifying treatments are driving the migraine Drugs market.

Opportunity

Biomarker-guided treatment, earlier diagnosis and new device-based therapies give the migraine Drugs market strong room to grow.

Market Restraints

Hard-to-reach brain targets, high failure rates in trials, side effects and high prices for new therapies hold back the migraine Drugs market.

Competitive Landscape for Migraine Drugs Market in APAC

The migraine Drugs market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Migraine Drugs Market in APAC

Migraine Drugs in APAC: rules, payment and research

In some of the countries we cover here, medicines are approved by TGA (Australia)⁠[1], NMPA (China)⁠[2], Drug Office (Hong Kong)⁠[3], CDSCO (India)⁠[4], PMDA (Japan)⁠[5], NPRA (Malaysia)⁠[6], Medsafe (New Zealand)⁠[7], FDA Philippines (Philippines)⁠[8], HSA (Singapore)⁠[9] and Thai FDA (Thailand)⁠[10]. How care is paid for in some of these countries: Medicare and the PBS (Australia)⁠[11], basic medical insurance (China)⁠[12], the Hospital Authority (Hong Kong)⁠[13], Ayushman Bharat PM-JAY (India)⁠[14], public health insurance (Japan)⁠[15], subsidised public care (Malaysia)⁠[16], Pharmac (New Zealand)⁠[17], PhilHealth (Philippines)⁠[18], MediShield Life (Singapore)⁠[19] and the Universal Coverage Scheme (Thailand)⁠[20]. ClinicalTrials.gov lists 58 studies on Migraine Drugs that are recruiting, active or about to start in APAC.⁠[21]

[1] Therapeutic Goods Administration. Checked 14 Nov 2026.

[2] National Medical Products Administration. Checked 14 Nov 2026.

[3] Drug Office, Department of Health. Checked 14 Nov 2026.

[4] Central Drugs Standard Control Organisation. Checked 14 Nov 2026.

[5] Pharmaceuticals and Medical Devices Agency. Checked 14 Nov 2026.

[6] National Pharmaceutical Regulatory Agency. Checked 14 Nov 2026.

[7] Medsafe. Checked 14 Nov 2026.

[8] Food and Drug Administration Philippines. Checked 14 Nov 2026.

[9] Health Sciences Authority. Checked 14 Nov 2026.

[10] Thai Food and Drug Administration. Checked 14 Nov 2026.

[11] Pharmaceutical Benefits Scheme. Checked 14 Nov 2026.

[12] National Healthcare Security Administration. Checked 14 Nov 2026.

[13] Hospital Authority. Checked 14 Nov 2026.

[14] National Health Authority (PM-JAY). Checked 14 Nov 2026.

[15] Ministry of Health, Labour and Welfare. Checked 14 Nov 2026.

[16] Ministry of Health Malaysia. Checked 14 Nov 2026.

[17] Pharmac. Checked 14 Nov 2026.

[18] PhilHealth. Checked 14 Nov 2026.

[19] CPF Board, MediShield Life. Checked 14 Nov 2026.

[20] National Health Security Office. Checked 14 Nov 2026.

[21] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in APAC. Retrieved 12 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for migraine Drugs. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in APAC.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Migraine Drugs right now, from free public sources.

Clinical trials

58 active trials in China, India, Japan, Australia, Hong Kong, Philippines, Singapore, Thailand, Malaysia, New Zealand, Bangladesh, Afghanistan, Indonesia, Myanmar, Nepal and Pakistan

Recruiting, about to start, or running now. Counted across the 16 countries we report on in APAC.

Top trial sponsors (worldwide)

  1. Pfizer Inc. 14 active trials on ClinicalTrials.gov (opens in a new tab)
  2. AbbVie Inc. 11 active trials on ClinicalTrials.gov (opens in a new tab)
  3. TriGemX Bio, Inc. 3 active trials on ClinicalTrials.gov (opens in a new tab)
  4. Ipsen 3 active trials on ClinicalTrials.gov (opens in a new tab)
  5. Lundbeck 3 active trials on ClinicalTrials.gov (opens in a new tab)

Source: ClinicalTrials.gov, Industry lead sponsors of active studies found with this market's trial search, worldwide. Retrieved 13 Nov 2026.

See every trial on ClinicalTrials.gov (opens in a new tab)

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Migraine Drugs in context

Free data on this topic

Quick answers

Frequently asked questions

How big is the Migraine Drugs market in Asia Pacific?
Placeholder estimate: about $2.03 Bn in 2025, rising to about $4.45 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Migraine Drugs market in Asia Pacific growing?
Placeholder estimate: about 9.1% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Migraine Drugs market report cover?
The report splits the market by drug class (CGRP Antibodies, Gepants, Triptans, Ditans and more), use (Acute Treatment, Prevention) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Migraine Drugs market?
Key players include Pfizer Inc., AbbVie Inc., Teva Pharmaceutical, Eli Lilly and Company, Amgen Inc. and Lundbeck.
What is driving the Migraine Drugs market?
An ageing population, more people living with brain and nerve diseases, better diagnosis and the first disease-modifying treatments are driving the migraine Drugs market.
How many clinical trials on Migraine Drugs are running in Asia Pacific?
58 studies are recruiting, active or about to start in Asia Pacific, counted across the 16 countries we report on there, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Asia Pacific. Retrieved 12 Nov 2026.
How much research is published on Migraine Drugs?
PubMed lists 60 papers on Migraine Drugs added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in APAC

See all

Related on brain and nerves and pain

See the topic